genuine question about tirzepatide that I am slightly embarrassed to ask
genuine question about tirzepatide that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Cosigning the four-week thing. It is a minimum interval, and treating it as a schedule to keep up with is how people end up miserable at 12.5.
the trials titrated on a calendar, real people titrate on symptoms
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme.
This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.
the muscle cramps profile is genuinely gentler than people expect coming from sema
Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
a lot of people plateau nicely at 10mg and never need 15
Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.
stepping every four weeks is a ceiling on speed, not a schedule you must hit
if 7.5 is working, 10 is not automatically better
switching from sema is not a dose conversion, there is no clean equivalence
switching from sema is not a dose conversion, there is no clean equivalence
blunt_coldbox29 is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.
sulphur burps are the signature complaint and they are not dangerous
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
hold the dose that works, the ladder is not a leaderboard
pens and vials are the same molecule, the price is the difference
zepbound and mounjaro are the same compound with different labels
Correction to my own post above — I said 10mg and I have been on 12.5mg since the spring. Same argument, wrong number.
the appetite effect is blunter than sema, in a good way, most weeks
Correction to my own post above — I said 10mg and I have been on 12.5mg since the spring.
Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.
Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.
Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.
2.5 is the starter dose and it is not meant to be the dose that works
the four-week step schedule is the label, not folklore
- 1Removed the conversion table. There is no published equivalence between the…8 comments in this branch · started by u/quiet_moderator
- 2Vials and pens carry the same molecule; what differs is fill volume, device…7 comments in this branch · started by u/emil_okwuosa